#Altimmune (ALT)

Altimmune  Altimmune ( ALT ) stock soared last Friday after speculation of a takeover by three large companies.  The speculation died today. Nevertheless, other news about this firm could be important...

Altimmune Third Quarter Financial Results Yesterday, October 12, 2024, Altimmune ( ALT ) announced financial results for the third quarter ended September 30, 2024, and provided a business update. Fro...

Altimmune Today, June 18, 2024, Altimmune ( ALT ) announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and M...

Prohost Letter #459 ~ NAFLD & NASH NAFLD is Non-Alcoholic Fatty Liver Disease, and NASH is Non-Alcoholic Steatohepatitis. We will start with NAFLD.   NAFLD The Non-Alcoholic Fatty Liver Disease is cau...

Immunovent, Altimmune & Soleno In addition to Vertex ( VRTX ) , Crispr Therapeutics ( CRSP )  and Acturus Therapeutics ( ARCT ) , the following summaries are of three firms we believe have promising P...

Altimmune Positive Topline Results Altimmune ( ALT ) announced positive results from the MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide.  Altimmune is a clinical-stage biopharmaceutical company...